The Center for Genomic Medicine

The Center for Genomic Medicine was established with the help of a grant obtained from the SECTORAL OPERATIONAL PROGRAM “INCREASING ECONOMIC COMPETITIVENESS” PRIORITY AXIS 2 -co-financed by the European Regional Development Fund, in 2015.

The Center for Genomic Medicine integrates interdisciplinary expertise in various medical specialties (neurology, psychiatry, cardiology, ophthalmology, nephrology, oncology, hematology, nutrition and diabetes, metabolic diseases, endocrinology), advances the molecular characterization of human disease, identification or validation of molecular targets for new, as well as innovative therapies.

The technological platforms of the Center allow research advancement in the post-genomic era, offering a paralleled approach for the development of new therapies in genetic or multifactorial diseases.

The Center for Genomic Medicine aims to be integrative for multiple fields. The areas of interest research are the result of previous collaborations and include: rare diseases, immunodeficiencies, rare cancers, identification of risk factors in obesity, personalized therapy, nutrigenomics, cardiogenetics, pharmacogenetics, etc.).

The Center for Genomic Medicine addresses different human disorders in collaboration with experienced researchers (in the clinics and the laboratories),  with the help of state of the art equipment, supported by a large existing Biobank of DNA.

Completed research projects

1. Operational Program for Competitiveness – POC-, Priority Axis 1: Attracting staff with advanced skills from abroad to strengthen R&D capacity, project: “Use of nutrigenomic models for personalization of dietary treatments in obesity”, contract no. 91/09.09.2016, ID P_37-684, MYSMIS code 104852.
2. Romania Moldova bilateral project “Increasing the capacity of genetic and genomic research in perinatal and child development” WB 29/2016

Ongoing research projects

1. Internal competition project 2019 5POSTDOC – The role of genome sequencing in the diagnosis of primary immunodeficiencies and rare cancers ACRONYM ImmunoGenomes (01.2020-01.2022) budget 50000 euro
2. Science and Technology in Childhood Obesity Policy (STOP) Project, Grant Agreement number 774548; Call: Horizon 2020-SFS-2016-2017; Topic: SFS-39-2017, Research Innovation Action 2018-2020.

Research directions:

rare diseases, rare cancers, primary immunodeficiencies, identification of risk factors in obesity, personalized therapy, nutrigenomics, cardiogenetics, pharmacogenetics.